When BCS IV Behaves Like BCS I: The Role of Smart Formulation, AI, and QbDin Future Medicines

Introduction:

Many modern drug molecules—particularly targeted and highly potent therapies—fail
not due to lack of efficacy, but because of poor biopharmaceutical properties. A large
proportion fall under BCS Class IV, characterized by low solubility and low
permeability, leading to variable absorption, food effects, and extensive reliance on
in vivo bioequivalence (BE) studies.

Although regulatory biowaivers are formally limited to BCS Class I drugs, advances
in formulation science, AI-driven modelling, and Quality by Design (QbD) now allow
BCS IV drug products to demonstrate BCS I–like in vivo performance, enabling
reduced clinical burden through science-based regulatory justification.

Why BCS IV Drugs Require a New Development Approach?

BCS IV drugs face dual barriers of dissolution and membrane transport, resulting in:

• Low and variable oral bioavailability
• Dose escalation and safety concerns
• Long development timelines

Modern development therefore relies on mechanistic, model-informed
formulation design rather than empirical trial-and-error.

Formulation Technologies Enabling BCS I–Like Performance

Amorphous Solid Dispersions (ASDs):

ASDs convert crystalline APIs into amorphous forms dispersed in polymers such as
HPMC-AS or PVP-VA.

Key benefits:

• 10–100× increase in apparent solubility
• Rapid dissolution and supersaturation
• Reduced food-effect variability

ASDs are now mature, scalable, and regulator-accepted platforms.

2. Lipid-Based Drug Delivery Systems (LBDDS):

SEDDS and SNEDDS maintain the drug in a solubilized state during GI transit.

Advantages:

• Bypass dissolution limitations
• Enhance permeability and lymphatic uptake
• Improve exposure of lipophilic BCS IV drugs

3. Nanocrystals and Nanosuspensions:

Particle size reduction to the nanometer range increases surface area and
dissolution velocity.

Impact:

• Rapid saturation at the absorption site
• Improved driving force for absorption
• Applicability across multiple routes

4. Permeability-Enhancing Formulations

For many BCS IV drugs, permeability is the primary limitation.
Approaches:

• Surfactants (e.g., TPGS, poloxamers)
• Tight-junction modulation
• Efflux inhibition

These strategies enhance effective permeability without altering the API.

5. Prodrug-Based Strategies:

Prodrugs improve solubility and transporter-mediated uptake, offering predictable
conversion and reduced variability—well aligned with targeted therapies.

6. Gastro-Retentive and Site-Specific Systems

Floating, mucoadhesive, and pH-responsive systems extend residence time at
optimal absorption sites, improving exposure for drugs with narrow absorption
windows.

7. Pharmaceutical Co-Crystals

Co-crystals modify crystal lattice properties without changing API identity, improving
solubility, dissolution, and manufacturability while supporting comparative
dissolution-based regulatory pathways.

8. AI- and QbD-Driven Formulation Design

The integration of AI with QbD represents a paradigm shift from empirical
development to predictive, regulator-friendly formulation science.

Role of QbD:

• Defines QTPP, CQAs, CMAs, and CPPs
• Establishes clear links between formulation variables and in vivo performance
• Enables mechanistic biowaiver justification

AI Applications:

• Predict solubility and permeability across physiological conditions
• Guide formulation platform and excipient selection
• Support PBPK modeling, IVIVC, and food-effect prediction

Digital Twins and Risk Management:

AI-assisted digital GI models and enhanced FMEA strengthen control strategies,
scale-up robustness, and lifecycle management—critical for biowaiver-like
approvals.

Alignment with Precision Medicine and Public Health:

• Targeted therapies: Enables consistent exposure of poorly soluble, high-
• potency drugs
• Personalised care: Supports flexible dosing and patient-centric formulations
• Scalability: Reduces development cost, timelines, and clinical burden
• Regulatory evolution: Advances model-informed, science-based approvals

Conclusion:

BCS IV drugs are no longer a dead end for oral development or regulatory flexibility.
Through advanced formulation technologies guided by AI and structured by
QbD, drug products can achieve BCS I–like in vivo performance, supporting
biowaiver-oriented strategies and accelerating access to precision medicines.
In the future of public health, formulation science—powered by digital tools—will
be as critical as molecular discovery itself.

Disclaimer:
This article is intended for scientific and educational discussion only. Regulatory
acceptance of biowaiver or biowaiver-like approaches depends on jurisdiction-
specific guidelines and product-specific evidence.